Efficacy observation of the two-drug regimen DTG+3TC in treatment-naive human immunodeficiency virus infection/acquired Immure deficiency syndrome patients

doi:10.19871/j.cnki.xfcrbzz.2023.06.007

Abstract

Abstract: Objective To investigate the clinical efficacy of a simplified regimen of dolutegr-avir(DTG)+lamivudine(3TC) in first-treatment human immunodeficiency virus infection/acquired immure deficiency syndrome patients. Method Historical control subgroups were selected, and primary HIV/AIDS patients who received antiretroviral therapy（ART）at the Chest Hospital of Guangxi Zhuang Autonomous Region between January 2019 and September 2022 were selected. According to the enrolment criteria, 47 cases in the observation group were treated with DTG+3TC regimen, and 49 cases in the control group were treated with tenofovir (TDF) + lamivudine (3TC) + efavirenz (EFV) regimen, and the HIV suppression rate and immunological status of the two groups were compared with each other after 36 weeks of treatment under observation. Result In the baseline characteristics of the two groups, the difference in age distribution and baseline HIV RNA load capacity were statistically significant, with no significant difference in residual baseline index; at 12 week of treatment, the observation group and control group were 56.6% and 30.6%, respectively(P=0.011); at 24 weeks of treatment, the viral suppression rates of the two groups were 63.6% and 79.6%, respectively (P=0.139); at 36 weeks treatment, the viral suppression rates of the two groups were 85.1% and 81.6%,respectively(P=0.786), and the median CD4⁺T lymphocyte counts and CD4⁺/CD8⁺T lymphocyte ratios were significantly higher than those at baseline, and there was no significant difference in the magnitude of the increase between the two groups(P>0.05). Conclusion The viral suppression effect of the simplified two-drug regimen of DTG+3TC in the treatment of first-treatment HIV/AIDS patients was not different from that of the triple-drug regimen of TDF+3TC+EFV, and even the early viral suppression rate was better than that of the triple-drug regimen of TDF+3TC+EFV, and at the same time it could effectively improve immune function.

Key words: Acquired immure deficiency syndrome, Dolutegravir, Lamivudine, Two-drug regimen, Clinical efficacy

CLC Number:

R512.91

Lan Shuanglai, Lan Ke, Zhang Yong, Dou Yangyun. Efficacy observation of the two-drug regimen DTG+3TC in treatment-naive human immunodeficiency virus infection/acquired Immure deficiency syndrome patients[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(6): 37-41.

References

[1] COLLINS SE, GRANT PM, SHAFER RW.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients[J]. Drugs, 2016, 76(1):75-98.
[2] JAMIELYNN C, SEBAAL Y, DENISE K.HIV Clinical Updates: New Single-Tablet Regimens[J]. Ann Pharmacother, 2019, 53(1):82-94.
[3] BOSWELL R, FOISY MM, HUGHES CA.Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review[J]. Ann Pharmacother, 2018, 52(7):681-689.
[4] VITORIA M, HILL A, FORD N, et al.The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?[J].AIDS, 2018, 32(12):1551-1561.
[5] MICHAEL SS, CONSTANCE AB, RAJESH TG, et al.Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel[J]. JAMA, 2018, 320(4):379-396.
[6] WHO. WHO-Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance[EB/OL].[2018-12-14].https://www.who.int/hiv/pub/guidelines/ARV2018update/en/.
[7] EUROPEAN AIDS CLINICAL SOCIETY. the European Guidelines for the treatment of HIV-positive adults in Europe (version10.0)[EB/OL].[2023-01-10].https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.htmL2019.
[8] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心.中国艾滋病诊疗指南(2018版)[J/CD].新发传染病电子杂志,2019,4(2):65-84.
[9] MARTA B, FRANCOIS V.The triumph of HIV treatment: another new antiretroviral[J]. Lancet, 2017, 390(10107): 2019-2021.
[10] CAHN P, MADERO JS, ARRIBAS JR, et al.Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind,randomised, non-inferiority, phase 3 trials[J]. Lancet, 2019, 393(10167):143-155.
[11] CAHN P, MADERO JS, ARRIBAS JR, et al.Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials[J].Acquir Immune Defic Syndr, 2020, 83(3):310-318.
[12] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中国艾滋病性病, 2021, 27(11):1182-1201.
[13] 凌雪梅, 蔡卫平, 钟活麟, 等. DTG+3TC简化方案真实世界临床疗效与安全性研究[J].传染病信息, 2022, 35(1):51-55.
[14] QUESADA PR, ESTEBAN LL, GARCIA JR, et al.Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients[J]. Int J Clin Pharm, 2015, 37(5): 865-872.
[15] LEE KH, KIM J, LEE JA,et al.Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea[J]. Viruses, 2022, 14(11):2558.
[16] KOTEFF J, BORLAND J, CHEN S, et al.A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects[J]. Br J Clin Pharmacol, 2013, 75(4):990-996.
[17] BOURGI K, JENKINS CA, REBEIRO PF, et al.North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada[J].Int AIDS Soc, 2020, 23(4):e25484.
[18] BOURGI K, REBEIRO PF, TURNER M, et al.Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy[J]. Clin Infect Dis, 2020, 70(7):1267-1274.
[19] MENARD A, MEDDEB L, TISSOT-DUPONT H, et al.Dolutegravir and weight gain: an unexpected bothering side effect?[J].AIDS, 2017, 31(10):1499-1500.
[20] RIZZARDO S, LANZAFAME M, LATTUADA E, et al.Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients[J].AIDS, 2019, 33(10):1673-1674.
[21] MAVE V, ERLANDSON KM, GUPTE N, et al.ACTG PEARLS and NWCS 319 Study Team.Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults[J].Infect Dis, 2016, 214(1):65-72.